Ya-Nan Yu

Dr. Ya-Nan Yu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
PSPengli Su
Pengli Su
KZKai Zhi
Kai Zhi
HXHuanhuan Xu
Huanhuan Xu
JXJing Xiao
Jing Xiao
JLJun Liu
Jun Liu
HDHai-Xia Dang
Hai-Xia Dang
Objectives: Multi-Criteria Decision Analysis (MCDA) has gained increasing attention in supporting drug risk-benefit assessment, pricing and reimbursement, as well as optimization of clinical interventions. The objective of this study was to systematically collect and categorize evaluation criteria and techniques of weighting and scoring of MCDA for drug value assessment.Methods: A systematic review of the literature was conducted across seven databases to identify articles utilizing the MCDA frameworks for the evaluation of drug value. Evaluation criteria mentioned in the included studies were extracted and assigned to 5 dimensions including clinical, economic, innovative, societal and humanistic value. A descriptive statistical analysis was performed on the identified drug value evaluation criteria, as well as the weighting and scoring techniques employed. The more a criterion or technique were mentioned in articles, the more important we consider it.Results: Out of the 82 articles included, 111 unique criteria were identified to evaluate the value of drug. Among the 56 unique criteria (448 times) used to measure clinical value, the most frequently mentioned were “comparative safety/tolerability” (58 times), “comparative effectiveness/efficacy” (56 times), “comparative patient-perceived health/patient reported outcomes” (37 times), “disease severity” (34 times), and “unmet needs” (25 times). Regarding economic value measurement, out of the 20 unique criteria (124 times), the most frequently utilized criteria were “cost of intervention” (17 times), “comparative other medical costs” (16 times), and “comparative non-medical costs” (18 times). Out of the 10 criteria (18 times) for assessing innovative value, “a novel pharmacological mechanism” was the most frequently mentioned criterion (5 times). Among the 22 criteria (73 times) used to measure societal value, “system capacity and appropriate use of intervention” was the most frequently cited criterion (14 times). Out of the 3 criteria (15 times) utilized to measure humanistic value, “political/historical/cultural context” was the most frequently mentioned criterion (9 times). Furthermore, 11 scoring and 11 weighting techniques were found from various MCDA frameworks. “Swing weighting” and “a direct rating scale” were the most frequently used techniques in included articles.Conclusion: This study comprehensively presented the current evaluation dimensions, criteria, and techniques for scoring and weighting in drug-oriented MCDA articles. By highlighting the frequently cited evaluation criteria and techniques for scoring and weighting, this analysis will provide a foundation to reasonably select appropriate evaluation criteria and technique in constructing the MCDA framework that aligns with research objectives.

18 September 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Yinli ShiYinli Shi
Yinli Shi
JLJun Liu
Jun Liu
SGShuang Guan
Shuang Guan
SWSicun Wang
Sicun Wang
CYChengcheng Yu
Chengcheng Yu
ZWzhong wang
zhong wang
Drug prediction and treatment using bioinformatics and large-scale modeling have emerged as pivotal research areas. This study proposes a novel multi-level collaboration framework named Syn-COM for feature extraction and data integration of diseases and drugs. The framework aims to explore optimal drug combinations and interactions by integrating molecular virtuality, similarity clustering, overlap area, and network distance. It uniquely combines the characteristics of Chinese herbal medicine with clinical experience and innovatively assesses drug interaction and correlation through a synergy matrix. Gouty arthritis (GA) was used as a case study to validate the framework’s reliability, leading to the identification of an effective drug combination for GA treatment, comprising Tamaricis Cacumen (Si = 0.73), Cuscutae Semen (Si = 0.68), Artemisiae Annuae Herba (Si = 0.62), Schizonepetae Herba (Si = 0.73), Gleditsiae Spina (Si = 0.89), Prunellae Spica (Si = 0.75), and Achyranthis Bidentatae Radix (Si = 0.62). The efficacy of the identified drug combination was confirmed through animal experiments and traditional Chinese medicine (TCM) component analysis. Results demonstrated significant reductions in the blood inflammatory factors IL1A, IL6, and uric acid, as well as downregulation of TGFB1, PTGS2, and MMP3 expression (p < 0.05), along with improvements in ankle joint swelling in GA mice. This drug combination notably enhances therapeutic outcomes in GA by targeting key genes, underscoring the potential of integrating traditional medicine with modern bioinformatics for effective disease treatment.

18 November 2024 in Science of Traditional Chinese Medicine
Verified
Journal Article
Open access
PSPengli Su
Pengli Su
KZKai Zhi
Kai Zhi
JXJing Xiao
Jing Xiao
HXHuanhuan Xu
Huanhuan Xu
JLJun Liu
Jun Liu
HDHaixia Dang
Haixia Dang
Objective: Danhong injection (DHI) is commonly used in China to treat chronic stable angina (CSA), demonstrating significant clinical efficacy and safety. The present study aimed to estimate the cost-effectiveness of DHI combined with standard treatment (ST) compared with ST alone in patients with CSA. Methods: A Markov model with a 3-month cycle and a 1-year time horizon was used to assess the cost-effectiveness of DHI + ST for CSA. Health outcomes were measured as quality-adjusted life years (QALYs), and societal perspective costs were collected in China. Cost-effectiveness was evaluated using the incremental cost-effectiveness ratio (ICER). Sensitivity analysis was performed to test the robustness of results to parameter uncertainty. Results: Analysis demonstrated DHI + ST provided 0.8190 QALYs at an average cost of $3644.24, while ST yielded 0.7884 QALYs costing $2739.54 over 1 year. The incremental analysis indicated DHI + ST dominance, with an ICER of $29,588.91 per QALY gained compared with ST. One-way sensitivity analysis confirmed the robustness of base case findings, and probabilistic sensitivity analysis suggested a 61.66% probability of DHI + ST being cost-effective over ST at a $37,663.26 per QALY threshold. Conclusion: From a societal perspective in China, DHI + ST appears cost-effective for the treatment of CSA compared with ST alone. These findings support recommending DHI as a clinically valuable and cost-effective option in CSA treatment guidelines.

24 March 2026 in Chinese Medicine
Verified
Journal Article
Open access
PDF file
Yinli ShiYinli Shi
Yinli Shi
JLJun Liu
Jun Liu
GZGuoduan Zeng
Guoduan Zeng
YWYuedan Wang
Yuedan Wang
SGShuang Guan
Shuang Guan
ZWzhong wang
zhong wang
Background: Bioinformatics and large-scale computational modelling have emerged as essential research fields in modern biomedical science, enabling drug discovery and therapeutic optimisation. A unique and potent technical framework for the modernisation and mechanistic clarification of traditional Chinese medicine (TCM) formulations is provided by the integration of multidimensional data using systems biology and artificial intelligence (AI) techniques. Methods: Ankylosing spondylitis–associated key hub genes were identified using multi-omics datasets, differential gene expression analysis, weighted gene co-expression network analysis, single-cell transcriptomic analysis, Mendelian randomization, and network module partitioning. In order to predict the optimal drug combinations and synergistic principal-auxiliary therapeutic roles, an interpretable, multi-layer graph convolutional network model was built using network topology features, molecular docking data, empirical clinical medication knowledge, and compound clustering similarity. Results: Eight AS-associated hub genes were found using AS as a representative disease model. A possible TCM formula, ASD-A, comprising Myrrha , Drynariae Rhizoma , Lycii Fructus , Epimedii Folium , Achyranthis Bidentatae Radix , Alpiniae Officinarum Rhizoma , Forsythiae Fructus , Astragali Radix, was prioritised by the proposed model. While ablation studies highlighted the crucial role of multi-source information integration in compound formula screening and the creation of customised intervention methods, model performance evaluation showed strong predictive potential. The identified hub genes were found to be tightly linked to immunological responses and T-cell-mediated immune processes, according to functional enrichment analyses. Experiments conducted both in vivo and in vitro confirmed that ASD-A significantly reduced pro-inflammatory cytokines like IL-6 and TNF-α ( P < 0.05), modulated the proportions of CD80 and CD86 cell subsets, and regulated the expression of important genes like KRAS, SMAD2, and MAPK14 ( P < 0.05). Furthermore, in activated Jurkat cells, ASD-A significantly decreased IL17 fluorescence while increasing Foxp3 fluorescence ( P < 0.05), indicating a rebalancing of the IL17/Foxp3 axis. The roles of major and auxiliary components in controlling hub gene activity were further clarified by formula decomposition analysis of ASD-A. Conclusion: The suggested AI-driven formula design approach provides new insights into combinatorial therapy approaches for AS while also conforming to the TCM theory of Jun-Chen-Zuo-Shi principle. The significant potential of combining contemporary bioinformatics and AI techniques with traditional medicine is demonstrated by this study, which could facilitate efficient and mechanistically informed disease therapy.